title: Initial clinical experience with the use of subcutaneous GR43175 in treating acute migraine.
abstract: Subcutaneous GR43175 was examined in patients with acute migraine for efficacy, tolerability and safety in an open, controlled, dose-ranging study. Ten patients with acute, non-medicated, migraine (15 attacks) were assessed for severity of headache and associated symptoms (nausea, vomiting and photophobia). GR43175 plasma samples were monitored serially after dosing. Doses of 2 mg or 3 mg gave rapid relief of all migraine symptoms. Thirteen attacks (86%) had either resolved completely or improved to a mild non-migraine residual headache within 40 min. Treatment was well tolerated at all doses, the only adverse effects being transient pain on injection. Peak plasma concentrations were obtained within 10-20 min; a decline in plasma drug concentration did not result in a relapse in headache severity.
authors.affiliation: Laboratoire de Pharmacologie, Hôpital Andre Mignot, Versailles.
authors.forename: N
authors.initials: N
authors.lastname: Brion
authors.forename: J
authors.initials: J
authors.lastname: Bons
authors.forename: J
authors.initials: J
authors.lastname: Plas
authors.forename: E M
authors.initials: EM
authors.lastname: Bayliss
authors.forename: C
authors.initials: C
authors.lastname: Advenier
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy*; D009325:Nausea / Q000139:chemically induced; D013449:Sulfonamides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018170:Sumatriptan
chemical_list: D007211:Indoles; D013449:Sulfonamides; D018170:Sumatriptan